Trending Now - Allen Institute Invests $400M in Genetic Therapies for Brain Health

WHO:

NPR - The Allen Institute, founded by Paul Allen in 2003, and his sister, Jody Allen.

NPR - Ed Lein, director of the institute's brain health programs.

NPR - John Ngai, senior investigator at the National Institutes of Health, who directs the BRAIN Initiative.

NPR - Jeff Carroll, a scientist involved in the accelerator effort.

WHAT:

NPR - The Allen Institute is launching a $400 million initiative called the Brain Health Accelerator.

NPR - The initiative aims to develop genetic therapies for neurodegenerative diseases including Alzheimer's, Parkinson's, ALS, and Huntington's.

NPR - The accelerator is an outgrowth of the BRAIN Initiative, which was unveiled by President Obama in 2013.

NPR - Genetic therapies have already shown success in treating spinal muscular atrophy, a rare genetic condition.

WHERE:

NPR - The Allen Institute is located in Seattle.

WHEN:

NPR - The BRAIN Initiative was unveiled in 2013.

WHY:

NPR - The goal of the Brain Health Accelerator is to translate knowledge about the brain into treatments for its disorders.

NPR - The initiative marks the first time the Allen Institute has made treating disease its primary goal.

HOW:

NPR - The accelerator will utilize genetic therapies, including gene editing and traditional gene therapy, to target specific genes related to brain disorders.

NPR - The Allen Institute's policy of making its databases available allows scientists globally to collaborate on research.

(UPDATED June 3, 2026 12:36 UTC)

The Allen Institute in Seattle is launching a groundbreaking $400 million initiative called the Brain Health Accelerator, aimed at developing genetic therapies for neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and Huntington's. This initiative, which is a direct outgrowth of the BRAIN Initiative introduced by President Obama in 2013, marks the first time the Allen Institute has prioritized treating disease as its primary goal. By utilizing advanced genetic therapies and making its databases accessible for global collaboration, the accelerator seeks to translate brain research into effective treatments for these challenging disorders.